We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Nanotherapeutic Prevents Spread of Cancer to the Liver in Mice

Nanotherapeutic Prevents Spread of Cancer to the Liver in Mice

Nanotherapeutic Prevents Spread of Cancer to the Liver in Mice

Nanotherapeutic Prevents Spread of Cancer to the Liver in Mice

Optimizing drug delivery characteristics from direct control over nanoparticle shape and size. Credit: Joseph DeSimone/ National Cancer Institute
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nanotherapeutic Prevents Spread of Cancer to the Liver in Mice"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Physician researchers from UT Southwestern Medical Center have developed an innovative nanotherapeutic drug that prevents cancer from spreading to the liver in mice.

The new liver-specific microRNA drug, developed by a team led by Andrew Wang, M.D., is a promising candidate for drug companies that developed messenger RNA (mRNA) vaccines for COVID-19, because of similarities in these RNA agents.

“This might be one ray of hope that comes out of the pandemic,” said Dr. Wang, Professor, Radiation Oncology, and author of a rodent-based study published in the journal Cancer Research.

“It takes major funding and resources to develop nanoparticles that can deliver nucleic acids such as mRNA and miRNA. Before the development of COVID-19 vaccines, the cost was prohibitive. But now that several platforms have been developed and approved, these platforms/nanoparticles can be utilized for other applications such as what we developed in in mice models in my lab,” added Dr. Wang, Radiation Oncology’s Associate Vice Chair for Research, and member of the Harold C. Simmons Comprehensive Cancer Center.

The study drug’s core was made by complexing miR-122 with calcium phosphate, and lipids were wrapped around the core to make the nanoparticle. The drug delivers the miR-122 into hepatocytes, which make them “healthier” by helping prevent cancer cells from establishing themselves in the liver. Although the drug has only been tested in mice, it is a valued advance in the fight against cancer, as up to 70 percent of people with conditions like colorectal cancer eventually develop liver metastases.

“Liver metastases are second only to lung metastases, so new therapeutics in this area are an urgent need in oncology. Dr. Wang’s study is promising because it showed minimal toxicity,” said Carlos L. Arteaga, M.D., Director of the Harold C. Simmons Comprehensive Cancer Center, who holds The Lisa K. Simmons Distinguished Chair in Comprehensive Oncology.

Reference: Sendi H, Yazdimamaghani M, Hu M, et al. Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis. Cancer Res. 2022;82(1):105-113. doi: 10.1158/0008-5472.CAN-21-2269


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.